MCID: BLT006
MIFTS: 50

Bilateral Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Bilateral Breast Cancer

MalaCards integrated aliases for Bilateral Breast Cancer:

Name: Bilateral Breast Cancer 12 52 14 69
Bilateral Breast Carcinoma 12 29

Classifications:



External Ids:

Disease Ontology 12 DOID:6741
NCIt 47 C8287
UMLS 69 C0281267

Summaries for Bilateral Breast Cancer

Disease Ontology : 12 A breast carcinoma that is characterized by an individual having breast cancer in both breasts, either simultaneously or at different times.

MalaCards based summary : Bilateral Breast Cancer, also known as bilateral breast carcinoma, is related to ductal carcinoma in situ and synchronous bilateral breast carcinoma. An important gene associated with Bilateral Breast Cancer is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Cell Cycle, Mitotic and DNA Double-Strand Break Repair. The drugs Diazepam and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and bone, and related phenotypes are Decreased homologous recombination repair frequency and cellular

Related Diseases for Bilateral Breast Cancer

Diseases related to Bilateral Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
id Related Disease Score Top Affiliating Genes
1 ductal carcinoma in situ 28.6 BRCA1 BRCA2 ERBB2 PGR
2 synchronous bilateral breast carcinoma 12.1
3 breast cancer 10.7
4 primitive neuroectodermal tumor of the corpus uteri 10.7 BRCA1 BRCA2
5 bronchopulmonary dysplasia 10.6 BRCA1 BRCA2
6 pancreatic cancer 4 10.6 BRCA1 BRCA2
7 cataract 27, nuclear progressive 10.6 BRCA1 BRCA2
8 eccrine sweat gland neoplasm 10.6 BRCA1 BRCA2
9 chronic frontal sinusitis 10.6 BRCA1 BRCA2
10 ovarian endometrioid adenofibroma 10.6 BRCA1 BRCA2
11 mediastinum synovial sarcoma 10.5 BRCA1 BRCA2
12 neutropenia, severe congenital, 6, autosomal recessive 10.5 BRCA2 RAD51
13 mycetoma 10.4 BRCA1 BRCA2
14 syndromic x-linked intellectual disability 14 10.3 BRCA1 BRCA2
15 mild hyperphenylalaninemia 10.3 ATM CHEK2
16 bowman's membrane folds or rupture 10.3 PGR RAD51
17 leukemia, acute lymphoblastic 10.2 ATM BRCA1 CHEK2
18 short-rib thoracic dysplasia 3 with or without polydactyly 10.2 ATM BRCA1 CHEK2
19 gastritis 10.2 ERBB2 PGR
20 glaucoma, hereditary 10.2 ERBB2 PGR
21 autoimmune disease of blood 10.2 BRCA1 BRCA2 PGR
22 selective immunoglobulin deficiency disease 10.2 BRCA1 BRCA2 PGR
23 skin sarcoma 10.1 ERBB2 PGR
24 her2-receptor negative breast cancer 10.1 ERBB2 PGR
25 breast pericanalicular fibroadenoma 10.1 BRCA1 BRCA2 PGR
26 subglottis verrucous carcinoma 10.1 ERBB2 PGR
27 retinal detachment 10.1 BRCA1 BRCA2 PGR
28 gastric tubular adenocarcinoma 10.1 ERBB2 PGR
29 her2-receptor positive breast cancer 10.1 ERBB2 PGR
30 nasal cavity squamous cell carcinoma 10.1 BRCA1 BRCA2 PGR
31 gastroesophageal junction adenocarcinoma 10.1 ERBB2 PGR
32 kallmann syndrome 10.1 ERBB2 PGR
33 colon neuroendocrine neoplasm 10.1 ERBB2 PGR
34 penis squamous cell carcinoma 10.1 ERBB2 PGR
35 breast fibrosarcoma 10.1 ERBB2 PGR
36 kidney clear cell sarcoma 10.1 ERBB2 PGR
37 dmd-related dilated cardiomyopathy 10.1 ERBB2 PGR
38 organ system benign neoplasm 10.1 ERBB2 PGR
39 cartilage cancer 10.1 ERBB2 PGR
40 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 10.1 ERBB2 PGR
41 cutaneous lupus erythematosus 10.1 BRCA1 BRCA2 ERBB2
42 hypersensitivity reaction type iii disease 10.0 ERBB2 PGR
43 endocervicitis 10.0 BRCA1 BRCA2 ERBB2
44 extracranial neuroblastoma 10.0 BRCA1 BRCA2 ERBB2
45 klatskin's tumor 10.0 ERBB2 PGR
46 comedo carcinoma 10.0 ERBB2 PGR
47 anal paget's disease 10.0 ERBB2 PGR
48 nail disorder, nonsyndromic congenital, 1 10.0 BRCA1 BRCA2 ERBB2
49 kidney benign neoplasm 10.0 ERBB2 PGR
50 fallopian tube papillary adenocarcinoma 10.0 ERBB2 PGR

Graphical network of the top 20 diseases related to Bilateral Breast Cancer:



Diseases related to Bilateral Breast Cancer

Symptoms & Phenotypes for Bilateral Breast Cancer

GenomeRNAi Phenotypes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.83 BRCA1 RAD51
2 Decreased homologous recombination repair frequency GR00151-A-2 10.83 BRCA1 RAD51
3 Decreased homologous recombination repair frequency GR00236-A-1 10.83 BRCA1 BRCA2 PALB2 RAD51 PGR
4 Decreased homologous recombination repair frequency GR00236-A-2 10.83 BRCA1 ATM BRCA2 PALB2 RAD51 PGR
5 Decreased homologous recombination repair frequency GR00236-A-3 10.83 BRCA1 BRCA2 PALB2 RAD51
6 Decreased viability GR00221-A-2 10.11 BRCA1 CHEK2
7 Decreased viability GR00221-A-3 10.11 ATM BRCA1 CHEK2 ERBB2
8 Decreased viability GR00221-A-4 10.11 ATM CHEK2 ERBB2
9 Decreased viability GR00301-A 10.11 BRCA1
10 Decreased viability GR00342-S-2 10.11 CHEK2
11 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.64 ATM BRCA1 BRCA2 CHEK2 PALB2
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.64 ATM BRCA1 BRCA2 CHEK2 PALB2 RAD51
13 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.63 ATM BRCA1 BRCA2 CHEK2 PALB2 RAD51
14 Decreased viability after ionizing radiation GR00232-A-2 9.5 ATM BRCA1 BRCA2
15 Decreased viability with cisplatin GR00101-A-4 9.43 BRCA1 BRCA2 RAD51
16 Synthetic lethal with cisplatin GR00101-A-1 9.13 BRCA1 BRCA2 RAD51

MGI Mouse Phenotypes related to Bilateral Breast Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.01 ATM BRCA1 BRCA2 CHEK2 ERBB2 PALB2
2 embryo MP:0005380 9.91 ATM BRCA1 BRCA2 ERBB2 PALB2 PGR
3 endocrine/exocrine gland MP:0005379 9.8 CHEK2 ERBB2 PGR ATM BRCA1 BRCA2
4 integument MP:0010771 9.8 FHIT PALB2 PGR ATM BRCA1 BRCA2
5 mortality/aging MP:0010768 9.61 ATM BRCA1 BRCA2 CHEK2 ERBB2 FHIT
6 limbs/digits/tail MP:0005371 9.55 BRCA1 BRCA2 ERBB2 PALB2 PGR
7 neoplasm MP:0002006 9.23 ATM BRCA1 BRCA2 CHEK2 ERBB2 FHIT

Drugs & Therapeutics for Bilateral Breast Cancer

Drugs for Bilateral Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 407)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 2 439-14-5 3016
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 50-02-2 5743
3
Carboplatin Approved Phase 4,Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
5
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
6
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
7
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
8
Goserelin Approved Phase 4,Phase 3,Phase 2 65807-02-5 47725 5311128
9
Tamoxifen Approved Phase 4,Phase 3,Phase 2 10540-29-1 2733526
10
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
11
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
12 Parecoxib Approved Phase 4 198470-84-7
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Clonidine Approved Phase 4,Phase 3 4205-90-7 2803
15
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
16
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
17
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
18
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
19
Remifentanil Approved Phase 4 132875-61-7 60815
20
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
21
Bupivacaine Approved, Investigational Phase 4,Phase 2 2180-92-9, 38396-39-3 2474
22
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
23
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
24
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
25
Fosaprepitant Approved Phase 4 172673-20-0 219090
26
B-Carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
27
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
28
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 3,Phase 1 114977-28-5 148124 9877265
29
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3,Phase 1 31703
30
Substance P Investigational Phase 4 33507-63-0 44359816
31 Anesthetics Phase 4,Phase 3,Phase 2
32 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Early Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Antiemetics Phase 4,Phase 2
37 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Early Phase 1
38 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Early Phase 1
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
40 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Autonomic Agents Phase 4,Phase 3,Phase 2
42 BB 1101 Phase 4,Phase 2,Phase 1
43 Cyclooxygenase Inhibitors Phase 4,Phase 3,Early Phase 1
44 Dexamethasone acetate Phase 4,Phase 2,Phase 1 1177-87-3
45 Gastrointestinal Agents Phase 4,Phase 2,Early Phase 1
46 glucocorticoids Phase 4,Phase 2
47 HIV Protease Inhibitors Phase 4,Phase 2
48 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 748)

id Name Status NCT ID Phase Drugs
1 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
2 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation Unknown status NCT01216254 Phase 4
3 Single-shot Pectoral Plane(PECs) Block Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECS Block and Local Anaesthetic Infusion After Breast Surgery: A Prospective Randomised, Double-blind Trial Completed NCT03024697 Phase 4
4 COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined Completed NCT01361789 Phase 4 parecoxib, valdecoxib, etoricoxib;Dexamethasone;parecoxib, valdecoxib, parecoxib and dexamethasone
5 Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment Completed NCT02061527 Phase 4
6 Sentinel Lymph Node Mapping Post-Injection Site Pain Completed NCT02065232 Phase 4 Tilmanocept;Sulfur Colloid
7 Low Level Laser Treatment and Breast Cancer Related Lymphedema Completed NCT00852930 Phase 4
8 Opioid Free Anesthesia: What About Patient Comfort? Completed NCT02882035 Phase 4
9 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
10 TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT Completed NCT01398982 Phase 4 Bupivacaine (study group);Isotonic saline (control group)
11 Infusion of a Local Anaesthetic in the Surgical After Modified Radical Mastectomy With Expander Completed NCT01389934 Phase 4 levo-bupicaine;Placebo
12 Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen Recruiting NCT02419742 Phase 4 Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Paclitaxel;Trastuzumab
13 Huaier Granule in Treating Women With Triple Negative Breast Cancer Recruiting NCT02615457 Phase 4 Huaier Granule
14 Tomosynthesis Versus Digital Mammography in a Population-based Screening Program Recruiting NCT02590315 Phase 4
15 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
16 A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Recruiting NCT03137368 Phase 4 Exemestane Tablets;Tamoxifen
17 Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. Active, not recruiting NCT01913990 Phase 4 Dexamethasone, Ondansetron, Aprepitant
18 Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner Active, not recruiting NCT02597452 Phase 4
19 Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial Active, not recruiting NCT01315015 Phase 4
20 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
21 Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients Unknown status NCT02078388 Phase 2, Phase 3 Doxorubicin
22 Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer Unknown status NCT00002460 Phase 3 goserelin acetate;tamoxifen citrate
23 Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer Unknown status NCT01452672 Phase 3
24 Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients Unknown status NCT00896155 Phase 3 Tamoxifen
25 Standard Versus Continuous Capecitabine in Advanced Breast Cancer Unknown status NCT00418028 Phase 2, Phase 3 drug: capecitabine;capecitabine
26 Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial Unknown status NCT00582244 Phase 3
27 Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer Unknown status NCT00525642 Phase 2, Phase 3 Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide;Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
28 Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates Unknown status NCT01236781 Phase 2, Phase 3
29 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Unknown status NCT01104571 Phase 3 lapatinib ditosylate
30 Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients Completed NCT00128310 Phase 3 gemcitabine
31 Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer Completed NCT00793377 Phase 3 Adriamycin (Doxorubicin), Docetaxel, Tamoxifen;Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
32 Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI Completed NCT01067976 Phase 3 Gadobutrol (Gadavist, Gadovist, BAY86-4875)
33 Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI) Completed NCT01104584 Phase 3 Gadobutrol (Gadavist, Gadovist, BAY86-4875)
34 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer Completed NCT00545077 Phase 3 Endocrine treatment consisting of either letrozole or fulvestrant.;Bevacizumab + Endocrine treatment consisting of either letrozole or fulvestrant.
35 Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer Completed NCT00140075 Phase 3 Epirubicin with Cyclophosphamide, followed by a Taxane;Epirubicin with a Taxane
36 Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine Completed NCT00294385 Phase 3 Docetaxel;Gemcitabine, Docetaxel;Docetaxel
37 Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer Completed NCT00003854 Phase 3
38 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
39 A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) Completed NCT00196872 Phase 3 Epirubicine;Cyclophosphamide;Taxol;Xeloda;Ibandronat
40 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 EC-T or TC plus GM1;EC-T or TC plus placebo
41 Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Completed NCT01953003 Phase 3 vinflunine;Capecitabine
42 BREAST CANCER AND EXERCISE Completed NCT00639210 Phase 3
43 Diet and Breast Cancer Prevention Trial Completed NCT00148057 Phase 3
44 Effects of Aerobic Exercise Versus Weight Training in Breast Cancer Survivors During Chemotherapy Completed NCT00115713 Phase 3
45 EC (Epirubicin, Cyclophosphamide) Followed by T (Docetaxel) Versus ET (Epirubicin, Docetaxel) Followed by X (Capecitabine) as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Patients Completed NCT00129935 Phase 3 epirubicin;docetaxel;capecitabine
46 A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer Completed NCT02054338 Phase 3 vinflunine 320 mg/m² as a 20-minute infusion on day 1 of each cycle repeated every 3 weeks gemcitabine 1000 mg/m² IV on day 1 and 8 repeated every 3 weeks;vinflunine plus gemcitabine;paclitaxel plus gemcitabine
47 PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer Completed NCT00236275 Phase 3 Fluoro-L-thymidine-(18F)
48 Physical Activity Promotion in Breast Cancer Survivors Completed NCT00221221 Phase 2, Phase 3
49 Does Scar Massage Improve Postoperative Pain and Function in Women With Breast Cancer? Completed NCT00175344 Phase 3
50 Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) Completed NCT00544232 Phase 3 Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa;Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa

Search NIH Clinical Center for Bilateral Breast Cancer

Genetic Tests for Bilateral Breast Cancer

Genetic tests related to Bilateral Breast Cancer:

id Genetic test Affiliating Genes
1 Bilateral Breast Carcinoma 29

Anatomical Context for Bilateral Breast Cancer

MalaCards organs/tissues related to Bilateral Breast Cancer:

39
Breast, Brain, Bone, Lymph Node, Testes, Skin, Lung

Publications for Bilateral Breast Cancer

Articles related to Bilateral Breast Cancer:

(show top 50) (show all 213)
id Title Authors Year
1
Synchronous Bilateral Breast Cancer With Discordant Histology. ( 28412779 )
2017
2
Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost. ( 28224401 )
2017
3
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. ( 28063331 )
2017
4
Gastric metastasis of bilateral breast cancer. ( 28280631 )
2017
5
First clinical report of helical tomotherapy with simultaneous integrated boost for synchronous bilateral breast cancer. ( 28707988 )
2017
6
Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome. ( 28139434 )
2017
7
Bilateral Breast Cancer After Prophylactic Bilateral Pulmonary Irradiation. ( 28272005 )
2017
8
PALB2 mutation in a woman with bilateral breast cancer: A case report. ( 28413668 )
2017
9
Treatment of bilateral breast cancer and regional nodes using an opposed lateral beam arrangement. ( 28867548 )
2017
10
Image-guided intensity-modulated radiotherapy for refractory bilateral breast cancer in a patient with extensive cutaneous metastasis in the chest and abdominal walls. ( 27284253 )
2016
11
Bilateral breast cancer resection performed under the bilateral transversus thoracic muscle plane block. ( 27555202 )
2016
12
Disease evolution and heterogeneity in bilateral breast cancer. ( 27904775 )
2016
13
Co-existence of a giant cell tumour of the tendon sheath and schwannoma in a patient with bilateral breast cancer: A potential cause of false positive findings in (18)F-FDG PET/CT studies. ( 27329560 )
2016
14
Challenges of treating incidental synchronous bilateral breast cancer with differing tumour biology. ( 27539136 )
2016
15
BILATERAL BREAST CANCER: DIAGNOSIS AND PROGNOSIS. ( 27483711 )
2016
16
Femoral Placement of Totally Implantable Venous Access Ports in Patients with Bilateral Breast Cancer. ( 26855441 )
2016
17
Helical tomotherapy for bilateral breast cancer: Clinical experience. ( 27253152 )
2016
18
Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer. ( 26933416 )
2016
19
Breast-Conserving Surgery in Bilateral Breast Cancer. ( 26265365 )
2015
20
Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer. ( 26399280 )
2015
21
Coexistence of systemic lupus erythematosus, Hashimoto's thyroiditis, and bilateral breast cancer in the same patient: a random association? ( 26399842 )
2015
22
Bilateral breast cancer following augmentation mammaplasty with polyacrylamide hydrogel injection: A case report. ( 26137129 )
2015
23
Use of tomotherapy in treatment of synchronous bilateral breast cancer: dosimetric comparison study. ( 25605345 )
2015
24
Impact of bilateral breast cancer on prognosis: synchronous versus metachronous tumors. ( 25735321 )
2015
25
A case of synchronous multiple bilateral breast cancer after breast augmentation. ( 26722625 )
2015
26
Bilateral breast cancer with a unilateral carcinoma within a fibroadenoma: A case report. ( 26622700 )
2015
27
Metabolic flare phenomenon on 18 fluoride-fluorodeoxy glucose positron emission tomography-computed tomography scans in a patient with bilateral breast cancer treated with second-line chemotherapy and bevacizumab. ( 25829734 )
2015
28
Bilateral breast cancer, synchronous and metachronous; differences and outcome. ( 26268697 )
2015
29
Multifocal Bilateral Breast Cancer and Breast Follicular Lymphoma: A Simple Coincidence? ( 26472982 )
2015
30
Surgical management for early-stage bilateral breast cancer patients in china. ( 25874699 )
2015
31
A clinicopathological study of early-stage synchronous bilateral breast cancer: a retrospective evaluation and prospective validation of potential risk factors. ( 24736632 )
2014
32
Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer. ( 25112434 )
2014
33
Primary Squamous Cell Carcinoma of the Breast After Cured Bilateral Breast Cancer. ( 25398815 )
2014
34
A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer. ( 24498881 )
2014
35
A rare recurrence of bilateral breast cancer in the esophagus coincidentally associated with primary gastric cancer: a case report. ( 24533645 )
2014
36
Morphoimmunohistochemical characteristics of synchronous bilateral breast cancer. ( 25257431 )
2014
37
Periductal stromal tumor of the breast with synchronous bilateral breast cancer. ( 24982380 )
2014
38
Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies. ( 25007962 )
2014
39
Primary synchronous bilateral breast cancer. ( 25494117 )
2014
40
Synchronous bilateral breast cancer in a male. ( 24319497 )
2013
41
Receptor status of tumor as prognostic factor in patients with bilateral breast cancer. ( 24382440 )
2013
42
Case report of small bowel obstruction caused by small intestinal metastasis of bilateral breast cancer. ( 24137245 )
2013
43
Histo-biological comparative analysis of bilateral breast cancer. ( 24062258 )
2013
44
The prognosis of synchronous and metachronous bilateral breast cancer in Chinese patients. ( 23296702 )
2013
45
A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. ( 23667202 )
2013
46
Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. ( 23104382 )
2013
47
A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character. ( 23875131 )
2013
48
The molecular and clinicopathologic characteristics of bilateral breast cancer. ( 24005135 )
2013
49
Survival from synchronous bilateral breast cancer: the experience of surgeons participating in the breast audit of the Society of Breast Surgeons of Australia and New Zealand. ( 22799341 )
2012
50
Dosimetric advantages of generalised equivalent uniform dose-based optimisation on dose-volume objectives in intensity-modulated radiotherapy planning for bilateral breast cancer. ( 23091290 )
2012

Variations for Bilateral Breast Cancer

Expression for Bilateral Breast Cancer

Search GEO for disease gene expression data for Bilateral Breast Cancer.

Pathways for Bilateral Breast Cancer

Pathways related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 ATM BRCA1 BRCA2 CHEK2 RAD51
2
Show member pathways
12.99 ATM BRCA1 BRCA2 CHEK2 PALB2 RAD51
3
Show member pathways
12.73 ATM BRCA1 BRCA2 CHEK2 RAD51
4
Show member pathways
12.46 ATM BRCA1 BRCA2 CHEK2 RAD51
5
Show member pathways
12.34 ATM BRCA1 BRCA2 RAD51
6
Show member pathways
12.33 ATM BRCA1 BRCA2 ERBB2 FHIT PGR
7 12.3 ATM BRCA1 BRCA2 CHEK2 RAD51
8
Show member pathways
12.24 ATM CHEK2 ERBB2
9
Show member pathways
12.21 ATM BRCA1 CHEK2 RAD51
10
Show member pathways
12.16 ATM BRCA1 CHEK2
11
Show member pathways
12.06 ATM BRCA1 CHEK2
12
Show member pathways
12.01 BRCA1 CHEK2 PGR
13
Show member pathways
11.95 ATM BRCA1 BRCA2 PALB2 RAD51
14 11.74 ATM BRCA1 BRCA2 CHEK2 RAD51
15 11.68 BRCA1 BRCA2 PALB2 RAD51
16 11.61 ATM BRCA1 ERBB2
17
Show member pathways
11.61 ATM BRCA1 CHEK2 RAD51
18
Show member pathways
11.54 ATM BRCA1 BRCA2 PALB2 RAD51
19 11.44 ATM BRCA1 CHEK2 ERBB2
20 11.38 ATM BRCA1 CHEK2
21 11.34 ATM BRCA1 CHEK2
22 11.31 ATM CHEK2
23
Show member pathways
11.3 ATM CHEK2
24 11.2 BRCA2 CHEK2
25 11.12 ATM BRCA1
26 11.12 ATM PGR
27 11.12 ATM BRCA1 RAD51
28 10.96 ATM CHEK2
29
Show member pathways
10.94 ATM BRCA1 BRCA2 CHEK2 RAD51
30 10.86 ATM BRCA1

GO Terms for Bilateral Breast Cancer

Cellular components related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.8 ATM BRCA1 BRCA2 CHEK2 PALB2 PGR
2 nucleus GO:0005634 9.61 ATM BRCA1 BRCA2 CHEK2 ERBB2 FHIT
3 condensed nuclear chromosome GO:0000794 9.37 BRCA1 RAD51
4 nuclear chromosome, telomeric region GO:0000784 9.33 ATM BRCA2 RAD51
5 condensed chromosome GO:0000793 9.32 BRCA1 RAD51
6 lateral element GO:0000800 8.8 BRCA1 BRCA2 RAD51

Biological processes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.93 ATM BRCA1 CHEK2 FHIT
2 cell cycle GO:0007049 9.92 ATM BRCA1 BRCA2 CHEK2
3 cellular response to DNA damage stimulus GO:0006974 9.85 ATM BRCA1 BRCA2 CHEK2 PALB2 RAD51
4 protein autophosphorylation GO:0046777 9.77 ATM CHEK2 ERBB2
5 regulation of signal transduction by p53 class mediator GO:1901796 9.76 ATM BRCA1 CHEK2
6 DNA recombination GO:0006310 9.73 BRCA1 BRCA2 PALB2 RAD51
7 DNA repair GO:0006281 9.73 ATM BRCA1 BRCA2 CHEK2 PALB2 RAD51
8 double-strand break repair GO:0006302 9.69 BRCA1 BRCA2 CHEK2
9 somitogenesis GO:0001756 9.64 ATM PALB2
10 response to gamma radiation GO:0010332 9.63 BRCA2 CHEK2
11 cellular response to gamma radiation GO:0071480 9.63 ATM CHEK2 RAD51
12 reciprocal meiotic recombination GO:0007131 9.62 ATM RAD51
13 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.62 ATM BRCA1 BRCA2 CHEK2
14 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.61 BRCA2 CHEK2
15 female gonad development GO:0008585 9.61 ATM BRCA2
16 response to X-ray GO:0010165 9.6 BRCA2 RAD51
17 DNA double-strand break processing GO:0000729 9.58 ATM BRCA1
18 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.58 BRCA1 BRCA2 CHEK2
19 inner cell mass cell proliferation GO:0001833 9.57 BRCA2 PALB2
20 replicative senescence GO:0090399 9.56 ATM CHEK2
21 telomere maintenance via recombination GO:0000722 9.55 BRCA2 RAD51
22 double-strand break repair via homologous recombination GO:0000724 9.55 ATM BRCA1 BRCA2 PALB2 RAD51
23 DNA damage induced protein phosphorylation GO:0006975 9.54 ATM CHEK2
24 chromosome organization involved in meiotic cell cycle GO:0070192 9.52 ATM RAD51
25 chordate embryonic development GO:0043009 9.49 BRCA1 BRCA2
26 mitotic recombination-dependent replication fork processing GO:1990426 9.48 BRCA2 RAD51
27 DNA synthesis involved in DNA repair GO:0000731 9.35 ATM BRCA1 BRCA2 PALB2 RAD51
28 strand displacement GO:0000732 9.02 ATM BRCA1 BRCA2 PALB2 RAD51

Molecular functions related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.63 ATM BRCA1 BRCA2 PALB2 PGR RAD51
2 protein C-terminus binding GO:0008022 9.13 BRCA2 ERBB2 RAD51
3 nucleotide binding GO:0000166 9.02 ATM CHEK2 ERBB2 FHIT RAD51

Sources for Bilateral Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....